readthroughSign in
Nov 12, 2026Quarterly update6 fact check notes

Sol-Gel completes Phase 3 enrollment follow-up for Gorlin syndrome drug, expects data late November

Sol-Gel Technologies reported last patient last visit in its SGT-610 pivotal trial and said it holds $45.7 million in cash and securities, with runway into early 2028.

The trial's primary endpoint is the number of new BCCs on the face at month 12 after twice-daily treatment, with secondary endpoints including the number of new surgically eligible BCCs, abbreviated as SEBs.1

Billingsley, MD, of Penn State College of Medicine; and Julie Breneiser, PA-C, of the Gorlin Syndrome Alliance.

The company said it continues to advance U.S. commercial readiness activities for SGT-610, and if approved, intends to retain full U.S. commercial rights and commercialize the drug through a cost-effective model using a third-party commercialization services organization and a small, focused field organization.1

On the balance sheet, Sol-Gel reported $14.4 million in cash, cash equivalents and deposits plus $31.3 million in marketable securities as of September 30, 2026, for a total of $45.7 million.1 The company said this is expected to fund cash requirements into the first quarter of 2028.1 Research and development expenses for the quarter were $5.1 million, down from $5.7 million in the same period of 2025.1

Fact check notes

  • Sentence removedSol-Gel Technologies said its pivotal Phase 3 trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome reached last patient last visit in September 2026.copied source wording
  • Sentence removedThe company announced on September 17, 2026 that the last patient had completed the last scheduled study visit in the trial, known as SGT-610-01, which is testing the drug for prevention of basal cell carcinoma lesions in adult patients with Gorlin syndrome.copied source wording
  • Sentence removedOf the 113 patients enrolled in the randomized, double-blind, vehicle-controlled study, 102 completed it, a completion rate of approximately 90%.copied source wording
  • Sentence removedTop-line results are expected in late November 2026.copied source wording
  • Sentence removedOn October 14, 2026, Sol-Gel hosted a KOL investor event in New York featuring Ervin Epstein Jr., MD, of Alta Bates Summit Medical Center; Kavita Sarin, MD, PhD, of Stanford Cancer Institute; Elizabeth M.copied source wording
  • Sentence removedThe event covered the disease burden of Gorlin syndrome, limitations of current surgical and off-label systemic management, and the potential role of SGT-610 in reducing the need for repeated surgeries.copied source wording

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.